$162.69
2.50%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
US76155X1000
Symbol
RVMD

Revolution Medicines Inc Stock News

Neutral
●
GlobeNewsWire
●
one day ago
REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pa...
Positive
●
Market Watch
●
12 days ago
Revolution Medicines' brand-new treatment brought in far higher sales than expected in its first few weeks on the market.
Neutral
●
Investors Business Daily
●
12 days ago
Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone.
Neutral
●
GlobeNewsWire
●
13 days ago
Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy Reported RASONQUE net product revenue of $198 million for the quarter, reflecting a partial quarter of sales following its U.S. commercial launch Received positive CHM...
Neutral
●
GlobeNewsWire
●
25 days ago
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that exploratory subgroup analyses from the Phase 3 RASolute 302 trial were presented as a late-breaking abstract at the Euro...
Neutral
●
GlobeNewsWire
●
28 days ago
REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, an investigationa...
Positive
●
Reuters
●
about one month ago
A European Medicines Agency committee on ​Thursday recommended approval of ‌Revolution Medicines' Rasonque in the EU for adults with pancreatic ​cancer that has spread ​and worsened after at least ⁠one prior treatment.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today